Kitamura K, Kangawa K, Ishiyama Y, Washimine H, Ichiki Y, Kawamoto M, Minamino N, Matsuo H, Eto T
First Department of Internal Medicine, Miyazaki Medical College, Japan.
FEBS Lett. 1994 Aug 29;351(1):35-7. doi: 10.1016/0014-5793(94)00810-8.
Proadrenomedullin N-terminal 20 peptide (PAMP) is a candidate for a novel biologically active peptide processed from an adrenomedullin precursor. Using a radioimmunoassay for human PAMP, major and minor immunoreactive PAMPs were purified from porcine adrenal medulla and complete amino acid sequences were determined. The major immunoreactive peptide was PAMP itself with an amidated carboxy terminus. The minor one was determined to be PAMP[5-20]. An intravenous bolus injection of human PAMP in anesthetized rats caused a rapid and strong hypotensive effect in a dose dependent manner. The present data indicate that PAMP is an endogenous biologically active peptide which is processed from adrenomedullin precursor.
前肾上腺髓质素N端20肽（PAMP）是一种从肾上腺髓质素前体加工而来的新型生物活性肽的候选物。使用针对人PAMP的放射免疫测定法，从猪肾上腺髓质中纯化出主要和次要免疫反应性PAMP，并确定了完整的氨基酸序列。主要免疫反应性肽是具有酰胺化羧基末端的PAMP本身。次要的被确定为PAMP[5-20]。在麻醉大鼠中静脉推注人PAMP会以剂量依赖的方式引起快速而强烈的降压作用。目前的数据表明，PAMP是一种从肾上腺髓质素前体加工而来的内源性生物活性肽。
